LIALDA demonstrated a steady 5-ASA release throughout the entire colon, with prolonged disintegration in the ascending colon. A post hoc analysis also found that patients could achieve complete symptom resolution after up to 16 weeks of LIALDA treatment.
A long-term safety study on Lialda found that the medication is generally well-tolerated, with most adverse events being mild or moderate in intensity. The study also showed that a majority of patients remained in remission for 12 months.
A post hoc analysis of a study on Lialda revealed significant improvements in time to symptom resolution for patients with mild to moderate ulcerative colitis. The study found that Lialda, an aminosalicylate medication, lowered the time to initial symptom resolution by up to 17 days compared to placebo.
A nationwide survey found that nearly three-quarters of UC patients consider feeling unwell normal, while only 37% of gastroenterologists agree. The study highlights the need for improved communication and compliance to address challenges in disease management.
A study using a dynamic in vitro gastrointestinal tract system demonstrated that LIALDA tablets release 5-aminosalicylic acid (5-ASA) over a prolonged period in the simulated colon, with nearly 90% of 5-ASA released in the fasted state. In contrast, minimal 5-ASA was released in the stomach and small intestine.
Post-hoc analyses of secondary endpoints from the long-term LIALDA trial show that the medication is effective in maintaining remission in various patient groups, including those with mild and moderate ulcerative colitis. The data also suggest that LIALDA can induce initial symptom resolution within weeks.
Long-term study results show that LIALDA (mesalamine) is effective in maintaining remission and preventing relapse in patients with mild to moderate ulcerative colitis. Nearly 9 out of 10 patients on once-daily LIALDA remained relapse free at the end of 12 months.
UC patients report a heavy psychological toll, with 82% experiencing increased stress and 62% feeling depressed. Nearly four out of five patients worry about long-term health effects, such as colon cancer or surgery. Non-compliance with medication is also a challenge, affecting up to half of patients.